GSK plc 6-K, filed Sep 1, 2023
GSK plc (GSK)
6-K
2023-09-01
For: 2023-09-01
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on September 1, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . .
..
Form 40-F . . . . . . . .
Issued: 01 September 2023, London UK
GSK's regulatory submission accepted
for review by Japanese regulator for use
of Nucala (mepolizumab)
in adults with chronic rhinosinusitis with nasal
polyps
●
If approved, Nucala would be the first anti-interleukin-5
biologic available in Japan for the treatment of adults with
inadequately controlled chronic rhinosinusitis with nasal polyps
(CRSwNP)
●
This
would be the third indication for mepolizumab in Japan for an IL-5
mediated condition
GSK plc (LSE/NYSE: GSK) today announced
that the Japanese Ministry of Health, Labour and Welfare (MHLW) has
accepted for review a supplementary new drug application (sJNDA)
for Nucala (mepolizumab), a
monoclonal antibody that targets interleukin-5
(IL-5), as a
treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in
adult patients.
The sJNDA is based on results of the pivotal phase III MERIT trial
which studied
the efficacy and safety of mepolizumab over a 52-week period in a
population of Japanese, Chinese and Russian patients with
inadequately controlled CRSwNP or eosinophilic chronic
rhinosinusitis (ECRS) as
well as data from the global phase III SYNAPSE study, which
explored the effect of mepolizumab vs. placebo in more than 400
patients with CRSwNP.1,2
CRSwNP/ECRS affects 2-4%
of the general population,2 In
Japan, it is estimated that there are 2 million people with chronic
sinusitis, of which about 200,000 are subject to surgery due to
nasal polyps.3 CRSwNP
is caused by chronic inflammation of the nasal
lining.2 Elevated
levels of IL-5 are associated with CRSwNP as a result of T2
inflammation, which
can cause soft tissue growth, known as nasal polyps that develop in
the sinuses and nasal cavity.2 People
with CRSwNP experience symptoms such as nasal obstruction, loss of
smell, facial pressure, sleep disturbance and nasal
discharge.2 Surgery
may be indicated for severe cases. However, polyps have a strong
tendency to reoccur, often leading to repeat
surgery.2
If approved, mepolizumab would be the first anti-IL-5 biologic for
adult patients with inadequately controlled CRSwNP in Japan.
Mepolizumab is approved in Japan as a treatment for bronchial
asthma in children aged 6 years or older and in adults with
refractory asthma whose symptoms are inadequately controlled with
standard treatment and also for the treatment of adult patients
with eosinophilic granulomatosis with polyangiitis (EGPA)
inadequately responding to the current treatment.
About the MERIT trial
The primary endpoints were change from baseline in
total endoscopic nasal polyp score at week 52 and change from
baseline in mean nasal obstruction visual analogue scale (VAS)
score during the 4 weeks prior to week 52.1 The
co-primary endpoints were met, and the efficacy and safety of
mepolizumab in the Japanese population were consistent with results
from global trials.1,2
About Nucala (mepolizumab)
First approved in 2015 for severe eosinophilic asthma (SEA) in the
US, mepolizumab is a unique monoclonal antibody that targets and
binds to interleukin-5 (IL-5), the major cytokine responsible for
the maturation and activation of eosinophils.4 The
administration of mepolizumab has shown to reduce the number of
blood eosinophils and maintain them within normal levels (normal
level of blood eosinophils being less than 500
eosinophils/microliter).4 Mepolizumab
has been developed for the treatment of a range of IL-5 mediated
diseases identified by elevated blood eosinophil
counts.4 Mepolizumab
has been studied in over 4,000 patients in 41 clinical trials
across several indications.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
1.
National
Library of Medicines (U.S.) (2021, February - 2023, April) Efficacy
and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis
With Nasal
2.
Polyps (CRSwNP)/ Eosinophilic Chronic
Rhinosinusitis (ECRS) (MERIT) NCT04607005
https://classic.clinicaltrials.gov/ct2/show/NCT04607005
3.
Han JK, et al. Mepolizumab for chronic rhinosinusitis with
nasal polyps (SYNAPSE): a randomised, double-blind,
placebo-controlled, phase 3 trial. The Lancet Respiratory
Medicine 2021 9 (10),
1141-1153
4.
Homepage of the Japan Intractable Diseases
Information Center https://www.nanbyou.or.jp/ Eosinophilic
sinusitis (Designated intractable disease 306)
5.
Nucala
(mepolizumab) SmPC available at
https://www.medicines.org.uk/emc/product/10563/smpc last accessed
August 2023.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
01, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|